

MICHAEL BRUCE NICHOLL, MD, FACS

South Texas Veterans Health Care System
Audie L. Murphy Memorial Hospital
7400 Merton Minter Blvd
San Antonio TX 78229
Office: (210) 617-5300 ext. 15491
Cell: (310) 584-4223
michael.nicholl@va.gov
drnicholl@outlook.com

EDUCATION

| | |
|---|-----------------|
| Senior Clinical Fellowship in Surgical Oncology | 7/2006 – 6/2009 |
| John Wayne Cancer Institute at Saint John's Health Center Santa Monica, CA | |
| Resident in General Surgery | 7/2000 – 6/2006 |
| Medical College of Wisconsin Affiliated Hospitals Milwaukee, WI | |
| Intern in General Surgery | 7/1999 – 6/2000 |
| Medical College of Wisconsin Affiliated Hospitals Milwaukee, WI | |
| Doctor of Medicine | 9/1995 – 5/1999 |
| MCP-Hahnemann University Philadelphia, PA | |
| Bachelor of Science—Physics | 9/1991 – 8/1995 |
| University of Pittsburgh, Pittsburgh, PA | |

APPOINTMENTS

| | |
|---|-------------------|
| Adjunct Assistant Professor of Clinical Surgery | 11/2014 – Present |
| University of Texas Health Sciences Center, San Antonio | |
| Staff Surgeon | 9/2014 – Present |
| Audie L. Murphy Hospital, South Texas Veterans Health Care San Antonio, TX | |
| Assistant Professor of Clinical Surgery | 7/2009 – 7/2014 |
| University of Missouri Columbia, MO | |
| Staff Physician | 10/2013 – 8/2014 |
| Harry S Truman VA Medical Center Columbia, MO | |
| Consultant Physician | 7/2009 – 10/2013 |
| Harry S Truman VA Medical Center Columbia, MO | |
| Courtesy Staff Physician | 7/2009 – 7/2014 |
| Boone Hospital Columbia, MO | |

| | |
|---|-----------------|
| Courtesy Staff Physician Valley Presbyterian Hospital Van Nuys, CA | 7/2008 – 1/2009 |
| Chief Administrative Fellow John Wayne Cancer Institute at Saint John's Health Center Santa Monica, CA | 7/2008 – 6/2009 |
| Administrative Chief Resident Medical College of Wisconsin Milwaukee, WI | 7/2005 – 6/2006 |

CERTIFICATION AND LICENSURE

| | |
|--|-------------------|
| Diplomat, American Board of Surgery (52043) | 12/2006 |
| –Recertification | 12/2015 |
| National Provider Identifier (1295877876) | 2/2007 |
| DEA Controlled Substance Registration | 11/2000 – 10/2016 |
| Texas Medical License (Q2595) | 12/2014 – 2/2017 |
| Texas Controlled Substances Registration | 12/2014 |
| California Medical License (A94797) | 4/2006 – 4/2018 |
| Wisconsin Medical License (42814-020) | 11/2000 – 10/2017 |
| Missouri Medical License (2009018162) | 6/2009 – 2/2015 |
| Missouri Bureau of Narcotics Registration (1567110014) | 7/2009 – 6/2014 |
| Zertifikat Deutsch als Fremdsprache | 6/1991 |

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

| | |
|--|----------------|
| Central Surgical Association | 2014 – Present |
| Americas Hepato-Pancreato-Biliary Association | 2009 – Present |
| International Hepato-Pancreato-Biliary Association | 2009 – Present |
| John Wayne Cancer Institute Alumni Association | 2009 – Present |
| Pancreas Club | 2009 – Present |
| Society for Surgery of the Alimentary Tract | 2008 – Present |
| American Association for Cancer Research | 2007 – Present |
| American Society of Clinical Oncology | 2006 – Present |
| Society of Surgical Oncology | 2006 – Present |
| Association for Academic Surgery | 2004 – Present |
| – <i>Information and Technology Committee, 2010-2011</i> | |
| – <i>Membership Committee, 2014-2016</i> | |
| American College of Surgeons | 2002 – Present |
| – <i>Fellow, 2011</i> | |

HONORS AND AWARDS

| | |
|--|---------|
| 2011 Outstanding Patient Educator Award, University of Missouri | 11/2011 |
|--|---------|

| | |
|--|-----------------|
| 2009 ASCO Cancer Foundation Merit Award | 11/2008 |
| Golden Scalpel Award for Outstanding Chief Resident, Medical College of Wisconsin | 6/2006 |
| William L. Donegan Surgical Oncology Research Award, Medical College of Wisconsin | 6/2003 |
| Sigma Pi Sigma Physics Honor Society | 8/1995 |
| University Honors Scholar, University of Pittsburgh | 8/1991 – 8/1995 |

COMMITTEE ASSIGNMENTS AND ADMINISTRATIVE SERVICES

| | |
|--|------------------|
| 1. NSQIP Surgical Champion, University of Missouri | 10/2010 – 7/2013 |
| 2. MUHC Quality and Patient Safety Committee —Cancer service line representative | 10/2010 – 7/2014 |
| 3. Cancer Liaison Physician—American College of Surgeons Committee on Cancer, Ellis Fischel Cancer Center | 1/2011 – 7/2014 |
| 4. Quality Improvement Subcommittee Ellis Fischel Cancer Center | 1/2011 – 7/2014 |
| 5. Robot Surgery Review Committee, University of Missouri | 6/2011 – 7/2014 |
| 6. Department of Pathology Faculty Search Committee, University of Missouri | 10/2011 – 1/2012 |
| 7. Research Council, University of Missouri | 7/2012 – 7/2014 |
| 8. Intuitive Surgical: daVinci robotic surgery procedure proctor | 9/2012 – 8/2013 |
| 9. Faculty Affairs Council, University of Missouri | 11/2012 – 7/2014 |
| 10. Institutional Biosafety Committee—ad hoc member, University of Missouri | 3/2014 – 7/2014 |
| 11. Surgical Oncology Tumor Board, Chair, STVHCS, San Antonio, TX | 11/2014—Present |
| 12. Cancer Committee, STVHCS | 11/2014—Present |
| 13. Medical Records Committee, STVHCS | 11/2014—Present |
| 14. Compensation Panel, STVHCS | 3/2015—Present |
| 15. Cancer Liaison Physician—ACS COC STVHCS | 1/2015—Present |

EDUCATIONAL ACTIVITIES

CLINICAL TEACHING

| | |
|---|-----------------|
| 1. Attending Surgeon, Division of Surgical Oncology, University of Missouri, Columbia, MO —Instruction of general surgery residents and medical | 7/2009 – 7/2014 |
|---|-----------------|

- students in the principles of surgical oncology and hepatopancreaticobiliary surgery.
2. **Surgical Management of Pancreas Cancer**, Division of Hematology/Oncology Fellows Lecture, University of Missouri, Columbia, MO 3/2010
 3. Lecturer, General Surgery Clerkship, University of Missouri —**Melanoma** 4/2010 – 7/2014
 4. Instructor, General Surgery Resident Laparoscopy Lab, University of Missouri —Minimally invasive hepatobiliary surgery 8/2010 – 7/2014
 5. Clinical Mentor, ACEs Program, University of Missouri 10/2010 – 7/2011
 6. **Pancreas Cancer: A Surgeon's Perspective**, Division of Hematology/Oncology Fellows Lecture, University of Missouri, Columbia, MO 10/2011
 7. Laboratory Mentor to Undergraduate Students, University of Missouri 7/2011 – 7/2014
 8. Laboratory Mentor to Surgical Residents, University of Missouri 7/2009 – 7/2014
 9. Clinical Research Mentor to Medical Students, University of Missouri 7/2009 – 7/2014
 10. Clinical Research Mentor to Surgical Residents, University of Missouri 7/2009 – 7/2014
 11. daVinci Procedure Proctor 9/2012 – 8/2013
 12. Staff Surgeon, General Surgery/Surgical Oncology STVHCS, San Antonio, TX 9/2014 – Present
—Instruction of UTHSCSA general surgery residents and medical students in the principles of general surgery, surgical oncology, and robotic surgery.

CME

1. **Pancreas Cancer: An Update for the General Practitioner**, Department of Family Medicine Grand Rounds, University of Missouri, Columbia, MO 2/2010
2. **Soft Tissue Sarcoma: Review of Management Principles**, Department of Surgery Grand Rounds, University of Missouri, Columbia, MO 4/2010
3. **Pancreas Cancer: A Surgeon's Perspective**, Hannibal Community Medical Society Meeting, Hannibal, MO 8/2010
4. **Surgical Management of Pancreas Cancer**, 2010 Oncology Nursing Review Course, University of Missouri, Columbia, MO 11/2010
5. **State of the Art in Pancreatic Cancer Care**, 2011 Clinical Oncology Symposium, Columbia, MO 4/2011

- | | |
|---|--------|
| 6. Pancreas Cancer Treatment: An Exercise in Futility? Department of Surgery Grand Rounds, University of Missouri, Columbia, MO | 9/2012 |
| 7. Surgery for Melanoma , Panel Discussion, Missouri Chapter of the American College of Surgeons Annual Meeting, Lake Ozark, MO | 6/2013 |
| 8. A Role for Interleukin-35 in Pancreas Cancer , Grand Rounds, UTHSCSA, San Antonio, TX | 1/2015 |

RESEARCH GRANTS AND FUNDING

1. Source and ID: University of Missouri, Department of Surgery
Project Title: Surgical Oncology Lab Start-up Funding
Project Period: 7/2010 – present
Role: Principle Investigator
Total Award: \$300,000
2. Source and ID: University of Missouri, Department of Surgery
Project Title: Urinary TH17 T-helper Cells and TH17 Specific Cytokines Following BCG Treatment of Superficial Bladder Cancer
Project Period: 2010 – 2011
Role: Mentor (Andrew Chang, MD, Urology Resident/Phillp Fuller, MD, Urology Resident)
Total Award: \$14,452
3. Source and ID: NewLink Genetics
Project Title: Phase III HyperAcute Pancreatic Cancer Vaccine Trial Protocol
Project Period: 2011- 2014
Role: PI for the University of Missouri
Total Award: \$60,359
4. Source and ID: University of Missouri, Department of Surgery
Project Title: Effect of Resveratrol on Radiosensitivity of Prostate Cancer
Project Period: 2011 – 2012
Role: Mentor (Bradley Moore, MD, Urology Resident)
Total Award: \$29,998
5. Source and ID: DOD
Project Title: In Vivo 18-FDG/18-Choline-Mediated Cerenkov Radiation Energy Transfer (CRET) Multiplexed Optical Imaging for Human Prostate Carcinoma Detection and Staging
Project Period: 2012 – 2013
Role: Co-PI (PI--Susan L. Deutcher, PhD)
Total Award: 2% effort
6. Source and ID: Grateful Patient Program (Miller Family)
Project Title: Resveratrol as a Radiosensitizer for Rectal Cancer
Project Period: 2012 – 2013
Role: PI

Total Award: \$5,000

7. Source and ID: University of Missouri, Department of Surgery
Project Title: A Role for Interleukin-35 in Human Melanoma
Project Period: 2013 – 2014
Role: Mentor (Thuan Nguyen/Plastic Surgery Resident)
Total Award: \$26,444

EDITORIAL WORK

1. Editorial Board: In Vivo
2. Editorial Board: Austin Journal of Surgery
3. Ad Hoc Reviewer: Journal of Laparoendoscopic & Advanced Surgical Techniques
4. Ad Hoc Reviewer: ILAR Journal
5. Ad Hoc Reviewer: Antibodies
6. Ad Hoc Reviewer: JOP—Journal of the Pancreas
7. Ad Hoc Reviewer: World Journal of Surgery

ABSTRACTS AND PRESENTATIONS

ORAL PRESENTATIONS

1. Invited Discussant. Alimentary Tract II Session. Surgical Forum, American College of Surgeons, Oct 2, 2012, Chicago, IL
2. Does specialized surgical training increase lymph node yield in colon cancer? Southern California Chapter of the American College of Surgeons, Jan 17, 2009, Santa Barbara, CA
3. Restored immune response to an MHC-II restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. American Academy of Pediatrics, Section on Surgery, Nov 1, 2003, New Orleans, LA
4. Local immune privilege promotes fibrosarcoma establishment. Surgical Forum, American College of Surgeons, Oct 6-10, 2002, San Francisco, CA

POSTER PRESENTATIONS

1. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis. Pancreas Club, May 2014, Chicago, IL.
2. IL-35 promotes melanoma growth by promoting proliferation and inhibiting apoptosis. Society of Surgical Oncology, Mar 2013, National Harbor, MD
3. Assessment of a novel immunological biomarker SNP panel from a phase III trial of Bacillus Calmette-Guerin (BCG) adjuvant treatment in stage III melanoma patients.. American Society of Clinical Oncology, June 2012, Chicago, IL
4. IL-33 inhibits proliferation and induces of apoptosis of pancreatic cancer cells. Society for Surgery of the Alimentary Tract, May 2012, San Diego, CA
5. IL-35 enhances pancreas cancer growth by promoting proliferation and inhibiting apoptosis. Pancreas Club, May 2012, San Diego, CA

6. A potential role for resveratrol as a radiation sensitizer for melanoma treatment. Society of Surgical Oncology, Mar 2012, Orlando, FL
7. IL-27 inhibits proliferation and promotes apoptosis of the SK-MEL-5 melanoma cell line. Society of Surgical Oncology, Mar 2012, Orlando, FL
8. A complex role for IL-17 in melanoma apoptosis and proliferation. Society of Surgical Oncology, Mar 2012, Orlando, FL
9. Unique presentation of pancreatic adenocarcinoma as a periampullary mass in a young patient, American College of Gastroenterology Annual Meeting, Oct 2011, National Harbor, Washington DC
10. Age influences likelihood of treatment, but not outcome, in pancreatic cancer. Society of Surgical Oncology, Mar 2011, San Antonio, TX
11. Effect of age on likelihood of treatment and outcome in pancreatic cancer. ASCO GI symposium, Jan 21, 2011, San Francisco, CA
12. Ten year review of melanoma with regression. MU Health Science Research Day, Nov, 2010, Columbia, MO
13. Does lack of surgical treatment contribute to disparities in race outcome in small bowel tumors? Coauthor, AACR--The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Feb 3, 2009, Carefree, AZ
14. Should microwave energy be preferred to radiofrequency energy for malignant liver tumor ablation? ASCO GI symposium, Jan 16, 2009, San Francisco, CA
15. Small bowel adenocarcinoma: understaged and undertreated? ASCO GI symposium, Jan 16, 2009, San Francisco, CA
16. Is lymphatic physiology to blame for the age paradox in melanoma? Coauthor, International Sentinel Node Congress, Feb 18-20, 2008, Sydney, Australia
17. T regulatory cells infiltrate murine fibrosarcoma and enhance tumor establishment. American Association for Cancer Research, July 11-14, 2003, Washington D.C.
18. Choledochal cysts in Western adults: complexities compared to children. Society for Surgery of the Alimentary Tract, May 2003, Orlando, FL

PUBLICATIONS

1. **Nicholl M**, Shilyansky J, Ota D. Management of malignant large bowel obstruction. *Contemp Surg* 2002; Aug:396-400.
2. **Nicholl M**, Pitt H, Wolf P, Cooney J, Kalayoglu M, Shilyansky J, Rikkers L. Choledochal cysts in Western adults: complexities compared to children. *J Gastrointest Surg* 2004; 8:245-52.
3. **Nicholl M**, Lodge A, Brown I, Sugg S, Shilyansky J. Restored immune response to an MHC-II restricted antigen in tumor-bearing hosts after elimination of regulatory T cells. *J Pediatr Surg* 2004; 39:941-6.
4. Lodge A, Yu P, **Nicholl M**, Brown I, Jackson C, Schreiber K, Sugg S, Schreiber H, Shilyansky J. CD 40 ligation restores cytolytic response and eliminates fibrosarcoma in the peritoneum of mice lacking CD4+ T cells. *Cancer Immunol Immunother* 2006; 55:1542-52.

5. **Nicholl MB**, Bilchik AJ. Radiofrequency ablation of colorectal carcinoma liver metastases. *Curr Colorectal Cancer Rep* 2007; 3:99-103.
6. **Nicholl MB**, Morton DL. Sentinel node biopsy in melanoma: standard of care. *Am J Hematol Oncol* 2007; 6:468-471.
7. **Nicholl M**, Bilchik AJ. Is routine use of sentinel node biopsy justified in colon cancer? *Ann Surg Oncol* 2008; 15:1-3.
8. **Nicholl MB**, Bilchik AJ. Thermal ablation of hepatic malignancy: useful but still not optimal. *Eur J Surg Oncol* 2008; 34:318-23.
9. Huang SK, Darfler MM, **Nicholl MB**, You J, Bemis KG, Tegeler TJ, Wang M, Wery J, Chong KK, Nguyen L, Scolyer RA, Hoon DSB. LC/MS-based quantitative proteomic analysis of paraffin-embedded archival melanomas reveals potential proteomic biomarkers associated with metastasis. *PLoS ONE* 2009; 4(2): e4430.
10. Conway WC, Faries MB, **Nicholl MB**, Terando AM, Glass EC, Sim M, Morton DL. Age-related lymphatic dysfunction in malignant melanoma patients. *Ann Surg Oncol* 2009; 16(6):1548-52.
11. **Nicholl MB**, Wright B, Conway WC, Aarnes-Leong T, Sim M, Faries M. Does specialized surgical training increase lymph node yield in colon cancer? *Am Surg* 2009; 75(10): 887-91.
12. **Nicholl MB**, Conway WC, Ye X, Bilchik A, Singh G. Should microwave energy be preferred to radiofrequency energy for malignant liver tumor ablation? *J Interventional Oncol* 2010; 3(1): 12-16.
13. **Nicholl MB**, Ahuja V, Conway WC, Vu VD, Sim M, Singh G. Small bowel adenocarcinoma: understaged and undertreated? *Ann Surg Oncol* 2010; 17(10):2728-32.
14. **Nicholl MB**, Takeuchi H, Elashoff D, Morton DL, Hoon DSB. Molecular upstaging of paraffin-embedded sentinel lymph nodes predicts long-term outcome in melanoma patients. *Ann Surg* 2011; 253(1):116-22.
15. Nguyen T, Kuo C, **Nicholl MB**, Sim M, Turner RR, Morton DL, Hoon DSB. Down-regulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. *Epigenetics* 2011; 6(3):388-94.
16. Fang Y, **Nicholl MB**. Sirtulin 1 in malignant transformation: Friend or foe? *Cancer Lett* 2011; 306(1):10-4.
17. Fang Y, Herrick EJ, **Nicholl MB**. Possible role for perforin and granzyme B in resveratrol enhanced radiosensitivity of prostate cancer. *J Androl* 2012; 33(4):752-60.
18. Fang Y, DeMarco VG, **Nicholl MB**. Resveratrol enhances radiation sensitivity in prostate cancer by inhibiting cell proliferation and promoting cell senescence and apoptosis. *Cancer Sci* 2012; 103(6):1090-8.
19. Fang Y, Moore BJ, Cook KM, Herrick EJ, **Nicholl MB**. A potential role for resveratrol as a radiation sensitizer for melanoma treatment. *J Surg Res* 2013; 183(2):645-53.
20. Fang Y, Moore BJ, Cook KM, Herrick EJ, **Nicholl MB**. Hydrogen peroxide enhances radiation induced apoptosis and inhibition of melanoma cell proliferation. *Anticancer Res* 2013; 33(5):1799-807

21. Macarthur KM, **Nicholl MB**. Principles and innovations in peritoneal surface malignancy treatment. *World J Oncol* 2013; 4(3):129-36.
22. Lyons DA, Coberly EA, Hammoud GM, **Nicholl MB**. Case Report of Pancreatic Dermoid Cyst and Discussion: Can Fine Needle Aspiration Make the Diagnosis? *JOP* 2013; 14(6):653-6.
23. **Fang Y, Nicholl MB**. A dual role for sirtuin 1 in tumorigenesis. *Curr Pharm Des* 2014; 20(15):2634-6.
24. **Nicholl MB**, Lyons D, Wheeler AA, Jorgensen JB. Repeat PEG placement is safe for head and neck cancer patients. *Am J Otolaryngol* 2014; 35(2):89-92.
25. Wheeler AA, **Nicholl MB**. Age influences likelihood of treatment, but not outcome, in pancreatic cancer. *World J Oncol* 2014; 5(1):7-13.
26. **Nicholl MB**, Ledgerwood CL, Chen X, Bai Q, Qin C, Cook KM, Herrick EJ, Diaz-Arias A, Moore BJ, Fang Y. IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition apoptosis: evidence for a role as an autocrine growth factor. *Cytokine* 2014; 70(2):126-133.
27. Ostermeyer AJ, **Nicholl MB**. Solid pseudopapillary tumor of the pancreas with massive cystic degeneration: source of diagnostic confusion. *Pancreat Disorders and Therapy* 2014; 4(3):1-3.
28. Fang Y, Chen X, Mohamud AO, Qin C, Bai Q, Cook KM, Herrick EJ, Ledgerwood CL, Davis MR, **Nicholl MB**. IL-9 inhibits melanoma cell growth through up regulation of p21 and TRAIL. *J Surg Oncol* 2015; 111(8):969-974
29. **Nicholl MB**, Chen X, Qin C, Bai Q, Zhu Z, Davis MR, Fang Y. IL-32 α has differential effects on proliferation and apoptosis of human melanoma cell lines. *J Surg Oncol* 2016; 113(4):364–369
30. MacArthur KM, Baumann BC, **Nicholl MB**. Laparoscopic versus open resection for gastrointestinal stromal tumors (GISTs). *J Gastrointest Cancer* 2016; epub ahead of print
31. Fang Y, Zhao L, Xiao H, Cook KM, Bai Q, Herrick EJ, Chen X, Qin C, Zhu Z, Wakefield MR, **Nicholl MB**. IL-33 acts as a foe MIA PaCa-2 pancreatic cancer. *Medical Oncology*; accepted for publication

REPORTS IN PREPARATION

1. **Nicholl MB**, Fang Y. IL-33 is a powerful constrainer for the growth of colon cancer cells.

BOOK CHAPTERS

1. **Nicholl MB**, Hoon DSB. Apoptosis in Cutaneous Melanoma. In: *Apoptosis in Carcinogenesis and Chemotherapy*, Chen GG, Lai PBS (eds). Springer, 2009.
2. **Nicholl MB**, Dale PS. Central Venous Access for Chemotherapy. In: *The Chemotherapy SourceBook, 5th Ed*, Perry MC, Doll DC, Freter CE (eds). Lippincott, Williams & Wilkins, 2012.